Utah will receive $150,000 from a $422.5 million settlement being paid to federal and state healthcare programs nationwide by a pharmaceutical company, Attorney General Mark Shurtleff said Monday.
Novartis Pharmaceutical Corp. settled over allegations of improper promotion of Trileptal, an anti-epileptic drug, for uses not approved by the Federal Drug Administration.
The settlement also resolves an investigation into alleged kickbacks to health care professionals for promoting and prescribing other drugs.
"Policing the pharmaceutical industry requires constant vigilance and a coordinated effort," Shurtleff said. "Holding companies accountable sends a message that we will not tolerate drug companies that violate the law."
The settlement requires the company to enter into an agreement that will be monitored by the U.S. Department of Health and Human Services inspector general's office.
No comments:
Post a Comment